Welcome to our dedicated page for Merit Medical Systems news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Medical Systems stock.
Merit Medical Systems Inc (NASDAQ: MMSI) is a leading manufacturer of medical devices used in diagnostic and interventional cardiology, radiology, and endoscopy procedures. Headquartered in South Jordan, Utah, the company employs approximately 7,000 individuals globally. Merit Medical's extensive product portfolio includes inflation devices for angioplasty and stent placement, diagnostic and therapeutic catheters, guide wires, thrombolytic catheters, fluid dispensing systems, angiography accessories, and custom angiography kits. The company's products are marketed across the United States, Europe, and around the world through direct sales forces and distributors.
Merit Medical operates primarily in two segments: Cardiovascular, which constitutes the majority of its revenue, and Endoscopy. The company is renowned for its innovative healthcare technology, with recent notable achievements including FDA 510(k) clearance for their SCOUT® MD™ Surgical Guidance System, designed to enhance the precision of tumor excision in breast cancer surgeries.
In 2024, Merit Medical commenced the MOTION study, a multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for treating knee osteoarthritis. This study underscores the company's commitment to evidence-based medicine and patient-centric care. Additionally, the company recently launched the Micro ACE Advanced Micro-Access System and the Siege Vascular Plug, which are expected to significantly improve patient outcomes in vascular procedures.
Financially, the company has introduced a Continued Growth Initiatives Program with robust targets set for 2026. Merit Medical has consistently focused on innovation, investment in research, and strategic expansion, making it a pivotal player in the medical technology sector.
For the latest updates and detailed financial data, Merit Medical Systems regularly schedules earnings calls and provides comprehensive reports which can be accessed by interested stakeholders.
Merit Medical Systems (NASDAQ: MMSI) announced plans to release findings from its WAVE study, examining the safety and efficacy of the WRAPSODY Cell-Impermeable Endoprosthesis for treating stenosis in the venous outflow circuit. The study enrolled 245 patients with arteriovenous fistula (AVF) stenosis and 113 with arteriovenous graft (AVG) stenosis.
Six-month safety and efficacy findings for the AVF cohort will be presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 14, 2024, in Lisbon. Additional presentations are scheduled at CIRSE and the Controversies in Dialysis Access (CiDA) Symposium in October.
The WRAPSODY device is not yet approved in the US but has received CE Mark for use in the European Union and is available in Brazil. Results from the WAVE study are expected to support Merit's Premarket Approval application to the FDA for commercial use in the United States.
Merit Medical has announced the acquisition of EndoGastric Solutions’ assets for $105 million, integrating the EsophyX Z+ device into its endoscopy portfolio. This device offers a minimally invasive treatment for chronic GERD. The acquisition is expected to add approximately $30 million in annual revenue, focusing on the gastrointestinal endoscopy market. Updated financial guidance for 2024 includes the partial-year impact, projecting revenue between $1.324 and $1.340 billion and diluted non-GAAP EPS between $3.22 and $3.31. Though initially dilutive to 2024 GAAP net income, the acquisition is expected to be accretive in the first full year post-closing.
Merit Medical Systems (NASDAQ: MMSI) will release its Q2 2024 financial results on August 1, 2024, after market close. The company will also host an investor conference call at 5:00 p.m. Eastern on the same day. Stakeholders can pre-register for the call and access a live webcast via links provided on merit.com.
Founded in 1987, Merit Medical Systems is a global leader in healthcare technology, specializing in disposable medical devices used in various medical procedures. The company employs around 7,000 people globally and serves hospitals worldwide with a robust sales and clinical support team.
Merit Medical Systems (NASDAQ: MMSI) has announced the US launch of the basixSKY Inflation Device, expanding its portfolio of inflation devices. The device, designed for ease of use and efficiency, is available as a standalone product or in kits with Merit Angioplasty Packs. It is intended for procedures like balloon angioplasty and stent placement, which restore blood flow through blocked arteries. Merit Medical aims to enhance its leadership in the inflation device market with this new offering.
Merit Medical Systems (NASDAQ: MMSI) announced the election of Silvia M. Perez to its Board of Directors during the Annual Meeting of Shareholders on May 15, 2024. Perez, who is currently the President of the Commercial Branding and Transportation Division at 3M Company, brings over two decades of healthcare industry experience, covering clinical, regulatory, operations, marketing, and business leadership. Perez, along with re-elected directors Fred P. Lampropoulos and Stephen C. Evans, will serve three-year terms. Perez's varied background includes roles such as President of Commercial Solutions Division and Vice President of Acelity at 3M, the company's largest acquisition. She holds a pharmaceutical chemist degree and Six Sigma certifications. Merit Medical emphasizes her potential to contribute valuable industry and organizational insights to support its growth initiatives.
Merit Medical Systems announced the appointment of Joe Wright as President, effective immediately. Wright, who has been with the company for 19 years, previously served as Chief Commercial Officer and President of the International Division. He will oversee global commercial, marketing, and manufacturing operations. The appointment is part of Merit’s Continued Growth Initiatives Program, which emphasizes investment in talent to drive growth and profitability. The company is also in the process of identifying a successor for CEO Fred P. Lampropoulos, who will retire at the end of 2025.
Merit Medical (NASDAQ: MMSI) has expanded its embolics portfolio with the FDA-cleared Siege Vascular Plug and the launch of Bearing nsPVA Express Prefilled Syringe in the US and Australia. These products complement existing microsphere, particle, and foam offerings. The Siege Vascular Plug, available in three sizes, offers rapid vessel occlusion within 1.3 minutes, enhancing precision in peripheral artery treatments. The Bearing nsPVA Express, a 20-mL prefilled syringe, simplifies procedures by saving time and reducing waste. Both products will be showcased at the 18th Annual GEST Meeting (May 16-19, 2024) in New York, where Merit will also exhibit other embolic solutions and delivery systems.
Merit Medical Systems, Inc. reported strong financial performance for Q1 2024 with a revenue increase of 8.7% to $323.5 million compared to Q1 2023. The company's GAAP operating margin improved to 11.1%, GAAP EPS rose to $0.48, and non-GAAP EPS increased to $0.77. Merit reaffirmed its fiscal year 2024 guidance with expectations of continued growth and profitability.
FAQ
What is the current stock price of Merit Medical Systems (MMSI)?
What is the market cap of Merit Medical Systems (MMSI)?
What does Merit Medical Systems Inc specialize in?
Where is Merit Medical Systems headquartered?
What are the main product segments of Merit Medical Systems?
What recent study has Merit Medical initiated?
What is the SCOUT® MD™ Surgical Guidance System?
How does Merit Medical distribute its products?
What is the significance of the Micro ACE Advanced Micro-Access System?
What is the Siege Vascular Plug used for?
What is Merit Medical's employment size?
What are some of the financial initiatives of Merit Medical?
